Last reviewed · How we verify

Lidocaine Hydrochloride and Ketamine

Rajmonda Nallbani-Komoni · FDA-approved active Small molecule Quality 5/100

Lidocaine Hydrochloride and Ketamine, marketed by Rajmonda Nallbani-Komoni, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's key strength lies in its unique combination of lidocaine and ketamine, which differentiates it from other anesthetic and pain management options. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic nameLidocaine Hydrochloride and Ketamine
Also known asLidocaine Hydrochloride ampule and Ketamine ampule
SponsorRajmonda Nallbani-Komoni
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: